41 A Case Series of Sarcomas

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 48

Background

Breast sarcomas are malignancies of mesenchymal cell lineages. They are rare and generally more aggressive than breast adenocarcinomas. The primary form arises de novo, and the secondary form is often treatment-related. Management remains highly variable. Experiences from retrospective studies and case reports can help identify patterns.

Methods

Summary of the 5 Patients' Breast Sarcoma Histology, Size, Grade, Staging, and Margins

Summary of the 5 Patients' Breast Sarcoma Histology, Size, Grade, Staging, and Margins

We discuss 5 cases: (1) 86F with a secondary angiosarcoma 6 years after lumpectomy/radiation to treat left breast mucinous carcinoma; (2) 44F with a 2-year history of an enlarging, biopsy-proven left breast angiosarcoma; (3) 39F with a 2-month history of an enlarging, biopsy-proven right breast angiosarcoma; (4) 60F with enlarging left breast mass on mammograms over 2 years with biopsies showing focal bone metaplasia; and (5) 59F with recurrent left breast phyllodes tumor.

Results

Patients 1 to 3 underwent mastectomy. With negative margins, patient 1 had a latissimus flap to cover the large wound. Three months later, she underwent excision of recurrent skin lesions and radiation. She declined palliative chemotherapy. Her cancer was upstaged from IIIB to IV after biopsy-confirmed liver metastasis at 1 year. Patient 2 completed gemcitabine/docetaxel and doxorubicin treatment but progressed from stage IIIA to IV with osseous and liver metastases at 1 year and died. Patient 3 was staged IIIA with medical and radiation oncology referrals. Patient 4 underwent an excisional biopsy, which returned spindle cell neoplasm with bone and cartilage differentiation. Despite margin clearance after re-excision and 2 cycles of gemcitabine/docetaxel to treat malignant phyllodes (initial diagnosis slightly favored over metaplastic carcinoma), she had a mastectomy for recurrence 6 months later. Immunohistochemistry showed keratin expression more characteristic of metaplastic carcinoma. The patient will initiate pembrolizumab. Patient 5 had lumpectomy. Her phyllodes tumor showed marked stromal atypia but was classified borderline given no overgrowth relative to epithelium and its liposarcoma differentiation, which has low malignant potential. A 1-cm margin was assured after re-excision. She will continue mammogram surveillance.

Conclusions

Large, high-grade histology such as angiosarcoma or spindle cell confer guarded prognosis. Their presence often warrants mastectomy +/- chemotherapy or radiation. Lumpectomy is considered for smaller tumors with favorable histology such as liposarcoma and benign/borderline phyllodes. Negative margin status is essential for disease control.

Articles in this issue

31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study
32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study
33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX
33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX
34 How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards
34 How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards
35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS
35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer
37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model
37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model
38 Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer
38 Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer
39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction:  A Nationwide Study
39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction: A Nationwide Study
40 Ethnic Disparities in Complication Rates and Outcomes  of Nipple-Sparing Mastectomy:  A Comprehensive Analysis
40 Ethnic Disparities in Complication Rates and Outcomes of Nipple-Sparing Mastectomy: A Comprehensive Analysis
41 A Case Series of Sarcomas
41 A Case Series of Sarcomas
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
Recent Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content